| Literature DB >> 22793786 |
Sofie Jacobson1, Eva Liedgren, Göran Johansson, Martin Ferm, Ola Winsö.
Abstract
BACKGROUND: Controversy exists regarding the influence of gender on sepsis events and outcome. Epidemiological data from other countries may not always apply to local circumstances. The aim of this study was to identify gender differences in patient characteristics, treatment, and outcome related to the occurrence of sepsis at admission to the ICU.Entities:
Mesh:
Year: 2012 PMID: 22793786 PMCID: PMC3497227 DOI: 10.3109/03009734.2012.703255
Source DB: PubMed Journal: Ups J Med Sci ISSN: 0300-9734 Impact factor: 2.384
Patient characteristics.
| Women | Men | |||
|---|---|---|---|---|
|
|
| |||
| No (%) | No (%) |
| ||
| Referral pattern | Admission from the community | 6 (12) | 10 (13) | ns |
| ICU transfer from within hospital | 35 (70) | 54 (70) | ns | |
| Transfer from other institution | 9 (18) | 13 (17) | ns | |
| Patient category | Medical | 28 (56) | 59 (76) | 0.019 |
| Surgical elective | 6 (12) | 9 (12) | ns | |
| Surgical emergency | 16 (32) | 9 (12) | 0.006 | |
| Co-morbidities | Congestive heart failure | 3 (6) | 3 (4) | ns |
| Chronic lung disease | 4 (8) | 4 (5) | ns | |
| Chronic liver disease | 0 (0) | 3 (4) | ns | |
| Chronic renal insufficiency | 1 (2) | 5 (6) | ns | |
| Diabetes | 11 (22) | 16 (21) | ns | |
| Cancer | ||||
| Haematological | 5 (10) | 8 (10) | ns | |
| Localized | 9 (18) | 9 (12) | ns | |
| Metastatic | 3 (6) | 3 (4) | ns | |
| Immunosuppressants | ||||
| Chronic steroids | 3 (6) | 6 (8) | ns | |
| Chemotherapy | 7 (14) | 8 (10) | ns | |
| Radiotherapy | 4 (8) | 2 (3) | ns | |
| Other immunosuppression | 2 (4) | 5 (6) | ns | |
| Other chronic disabling conditions | 7 (14) | 19 (25) | ns | |
| Number of co-morbidities | 0 | 19 (38) | 22 (28) | ns |
| 1 | 11 (22) | 29 (38) | ns | |
| 2 | 9 (18) | 18 (23) | ns | |
| >3 | 11 (22) | 8 (10) | ns | |
| Infection characteristics | Community-acquired | 35 (70) | 58 (75) | ns |
| Nosocomial | 15 (30) | 19 (24) | ns | |
| Primary infection site | Pneumonia | 10 (20) | 17 (22) | ns |
| Abdominopelvic | 17 (34) | 8 (10) | 0.002 | |
| Urinary tract | 3 (6) | 14 (18) | ns | |
| Other | 14 (28) | 23 (30) | ns | |
| Skin or skin structures | 0 (0) | 9 (12) | 0.012 | |
| Indwelling catheter | 4 (8) | 3 (4) | ns | |
| Unknown | 2 (4) | 3 (4) | ns | |
| Micro-organism | Gram-positive cocci | 18 (36) | 27 (35) | ns |
| Gram-positive rods | 0 (0) | 2 (3) | ns | |
| Gram-negative rods | 11 (22) | 19 (24) | ns | |
| Fungi | 6 (12) | 8 (10) | ns | |
| Other | 3 (6) | 7 (9) | ns | |
| Mixture | 5 (10) | 5 (6) | ns |
Other chronic disabling conditions include patients with Myelomeningocele and urinary bladder dysfunction, patients with tetraplegia of various underlying causes, patients with inflammatory bowel disease, and patients with multiple diseases other than those defined above. Other immunosuppressant includes azathioprine, ciclosporin, and TNF-α inhibitors. Community-acquired defined as infection developed within 48 hours after hospital admittance. Type of micro-organism retrieved from cultures from blood, urine, cerebrospinal fluid, synovial fluid, pleural fluid, and tissues.
aStatistically significant difference between genders.
Treatment, fluids, and antibiotics.
| A. Treatment | Women | Duration (days) | Men | Duration (days) | |||
|---|---|---|---|---|---|---|---|
| Modality | No (%) | Median (25/75 percentile) | No (%) | Median (25/75 percentile) |
| ||
| Vasopressor support | 37 (74) | 5.0 (2.0/6.5) | 55 (71) | 3 (2.0/7.0) | ns | ||
| Endotracheally intubated | 34 (68) | 7.5 (4.0/8.0) | 48 (62) | 8 (4.0/8.0) | ns | ||
| CRRT/HD | 12 (24) | 7.0 (5.0/8.0) | 15 (19) | 8 (3.0/8.0) | ns | ||
| Low-dose steroids | 28 (56) | 6.5 (4.0/8.0) | 41 (53) | 7 (2.0/8.0) | ns | ||
| Sedation | 36 (72) | 8.0 (4.0/8.0) | 51 (66) | 7 (3.0/8.0) | ns | ||
| Parenteral nutrition | 37 (74) | 5.0 (2.0/8.0) | 52 (68) | 5 (2.0/8.0) | ns | ||
| Enteral nutrition | 37 (74) | 5.0 (2.5/8.0) | 56 (73) | 6 (2.0/8.0) | ns | ||
| Platelet transfusion | 12 (24) | 2.5 (1.0/4.0) | 19 (25) | 1 (1.0/3.0) | ns | ||
| Low-molecular-weight heparin | 39 (78) | 7.0 (3.0/8.0) | 56 (73) | 7 (3.0/8.0) | ns | ||
| Surgical procedures | 25 (50) | 24 (31) | 0.041 | ||||
| Monitoring | |||||||
| Echocardiography | 27 (54) | 43 (56) | ns | ||||
| PiCCO | 14 (28) | 19 (25) | ns | ||||
| Total volume at 2 hours | 43 (86) | 2.0 (1.0/2.5) | 63 (82) | 2.0 (1.0/3.5) | ns | ||
| 24 hours | |||||||
| Crystalloids | 44 (88) | 2.6 (1.0/4.0) | 71 (92) | 3.0 (2.0/5.0) | ns | ||
| Human albumin 5% | 38 (76) | 1.0 (0.5/1.6) | 45 (68) | 1.0 (0.8/1.5) | ns | ||
| Human albumin 20% | 27 (64) | 0.2 (0.1/0.4) | 46 (60) | 0.2 (0.1/0.4) | ns | ||
| Synthetic colloids | 21 (42) | 1.0 (0.5/1.0) | 30 (39) | 1.0 (0.5/1.5) | ns | ||
| Total volume at 24 hours | 48 (96) | 4.0 (2.0/5.7) | 77 (100) | 3.8 (2.5/6.2) | ns | ||
| Fresh frozen plasma | 24 (48) | 1.0 (0.5/1.7) | 35 (44) | 1.0 (0.5/1.5) | ns | ||
| Red blood cells | 36 (72) | 0.8 (0.6/1.2) | 41 (53) | 0.6 (0.6/1.2) | 0.042 | ||
| ICU-LOS | |||||||
| Human albumin 5% | 46 (92) | 2.2 (1.0/3.7) | 64 (83) | 2.2 (1.0/3.8) | ns | ||
| Human albumin 20% | 39 (78) | 0.5 (0.3/1.2) | 55 (71) | 0.5 (0.2/1.2) | ns | ||
| Synthetic colloids | 24 (48) | 0.9 (0.5/1.4) | 42 (54) | 1.0 (0.5/2.0 | ns | ||
| Fresh frozen plasma | 29 (58) | 1.5 (1.0/3.8) | 42 (54) | 1.8 (0.5/3.3) | ns | ||
| Red blood cells | 40 (80) | 1.4 (0.8/2.3) | 52 (67) | 1.2 (0.6/2.6) | ns | ||
| Platelets | 12 (24) | 0.8 (0.3/1.4) | 19 (25) | 0.6 (0.3/1.2) | ns | ||
| Meropenem | 23 (46) | 11 (6/28) | 42 (54) | 17 (9/24) | ns | ||
| Ciprofloxacin | 21 (42) | 9 (2/15) | 29 (38) | 10 (4/14) | ns | ||
| Piperacillin/tazobactam | 20 (40) | 16 (6/33) | 28 (36) | 10 (5/24) | ns | ||
| Cefuroxime | 11 (22) | 9 (4/23) | 16 (21) | 1 (1/4) | 0.025 | ||
| Clindamycin | 8 (16) | 11 (3/41) | 19 (25) | 18 (8/33) | ns | ||
| Vancomycin/teicoplanin | 9 (18) | 6 (3/15) | 18 (23) | 3,5 (1/13) | ns | ||
| Aminoglycosides | 11 (22) | 8 (1/14) | 15 (19) | 3 (2/4) | ns | ||
| Cefotaxim/ceftazidim | 6 (12) | 18 (9/25) | 13 (17) | 12 (3/23) | ns | ||
| Ampicillin | 5 (10) | 9 (9/18) | 10 (13) | 6 (3/9) | 0.036 | ||
| Antimycotics (J02A) | 20 (40) | 29 (38) | ns | ||||
Surgical procedures include removal of gastrointestinal, biliary, and urinary obstructions; debridement; drainages of abscesses, pleural space, joints, and surgical drainagesa.
Crystalloids defined as Ringer's acetate and isotonic NaCl; synthetic colloid solutions include hydroxyethyl starch 130/0.4 6%, hydroxyethyl starch 200/0.5 6%, and dextran 70, 6%; blood products include packed red blood cells, fresh frozen plasma, and platelets. Total volumes at 2 and 24 hours defined as fluid administered for purpose of volume substitution (maintenance drip, nutritional solutions, infusions, and blood products excluded). Aminoglycosides include netilmicin, amikacin, gentamicin. Benzyl penicillin and tetracycline are omitted from the table; for information see text.
aStatistically significant difference between genders.
CRRT = continuous renal replacement therapy; HD = haemodialysis; LOS = length of stay; PiCCO = pulse contour intermittent thermodilution continuous cardiac output monitoring.
Scoring and outcome.
| Women | Men | ||||
|---|---|---|---|---|---|
| Mean | SD | Mean | SD |
| |
| Age (years) | 61.3 | 15.66 | 63.3 | 13.63 | ns |
| Scoring (point) | |||||
| APACHE II score | 19.6 | 6.01 | 20.0 | 6.88 | ns |
| SOFA_0 | 7.5 | 3.88 | 8.1 | 3.87 | ns |
| SOFA_1 | 8.5 | 4.54 | 7.4 | 4.17 | ns |
| SOFA_max | 9.4 | 4.45 | 10.2 | 4.27 | ns |
| TISS 76/ICU day | 26.1 | 8.13 | 26.9 | 9.50 | ns |
| LOS (days) | Median | 25/75 percentile | Median | 25/75 percentile | |
| ICU | 8 | (3/13.2) | 6 | (3/13) | ns |
| Survivors | 7 | (3.2/13.8) | 8 | (3.2/14.8) | ns |
| Non-survivors | 8.5 | (2/14.2) | 3 | (2/8.5) | ns |
| Hospital | 24.5 | (12/37) | 17 | (9/35) | 0.055 |
| Survivors | 31 | (15/64) | 18 | (12/35.5) | 0.082 |
| Non-survivors | 18 | (9/22) | 8 | (3/34) | ns |
| Mortality (%) | No (%) | 95% CI | No (%) | 95% CI | |
| ICU | 10 (20) | 0.11–0.33 | 17 (22) | 0.14–0.33 | ns |
| 28 days | 12 (24) | 0.14–0.38 | 22 (29) | 0.20–0.40 | ns |
| Hospital | 11 (22) | 0.13–0.35 | 25 (32) | 0.23–0.44 | ns |
| 3 months | 12 (24) | 0.14–0.38 | 30 (39) | 0.29–0.50 | ns |
| 6 months | 15 (30) | 0.19–0.44 | 32 (42) | 0.31–0.53 | ns |
| 1 year | 21 (42) | 0.29–0.56 | 35 (46) | 0.35–0.57 | ns |
| 2 years | 21 (42) | 0.29–0.56 | 35 (46) | 0.35–0.57 | ns |
SOFA_0 defined as SOFA at admission; SOFA_1 based on the highest values during the first whole 24-hour period from 06.00 to 06.00; and SOFA_max defined as the highest score during the ICU-LOS.
APACHE II = Acute Physiology and Chronic Health Evaluation score; SOFA = Sequential Organ Failure score; TISS 76 = Therapeutic Intervention Scoring System (76 items); ICU = intensive care unit; LOS = length of stay.
Figure 1.Proportion of patients with SOFA organ sub-score ≥3 as a sign of organ failure (females and males) and proportion of patients with SOFA organ sub-score <3 (females and males). SOFA sub-scores: circ = circulatory; resp = respiratory; renal = renal; coag = coagulation; CNS = central nervous system; hep = liver function.
Figure 2.Differences between genders in SOFA scores and CRP max in relation to hospital outcome. Panel A: SOFA score at admission (SOFA_0) was significantly higher in non-surviving than surviving women (P = 0.001), but not among surviving compared to non-surviving men. Panel B: SOFA score day 1 (SOFA_1) was significantly higher among hospital non-surviving compared to surviving women (P = 0.008), but in men SOFA_1 was significantly lower in non-surviving men compared to surviving men (P = 0.035). Panel C: SOFA_max was significantly higher among hospital non-survivors compared to survivors in both women (P = 0.001) and men (P = 0.017). Panel D: The interaction between gender and CRP as a risk factor for hospital mortality. CRP_max was significantly lower in surviving women than in non-surviving women (P = 0.035). Men displayed a different pattern with higher CRP in surviving men than non-surviving men, although the difference was not statistically significant (P = 0.081). (CRP = C-reactive protein. Data are presented as mean ± 95% confidence intervals).
Analysis of risk factors for hospital death.
| Univariate logistic regression analysis | Unadjusted odds ratio (95% CI) | ||
|---|---|---|---|
| Background variables | OR | 95% CI |
|
| Gender | 1.70 | (0.75–3.88) | 0.203 |
| Age (years) | 1.05 | (1.01–1.08) | 0.007 |
| Admission type medical | 2.98 | (1.13–7.90) | 0.028 |
| APACHE II | 1.12 | (1.05–1.20) | 0.001 |
| SOFA_0 | 1.22 | (1.09–1.36) | < 0.001 |
| SOFA_1 | 1.01 | (0.92–1.10) | 0.883 |
| SOFA_max | 1.26 | (1.13–1.41) | < 0.001 |
| Haematological disease | 7.25 | (2.07–25.42) | 0.002 |
| Chronic corticosteroid medication | 10.74 | (2.11–54.62) | 0.004 |
| Septic shock | 2.65 | (1.11–6.31) | 0.028 |
| C-reactive protein | 1.00 | (0.997–1.004) | 0.621 |
| Unadjusted odds ratio (95% CI) | |||
| Treatment modalities | OR | 95% CI |
|
| Vasopressor support | 1.13 | (0.99–1.29) | 0.076 |
| Endotracheally intubated | 0.98 | (0.89–1.10) | 0.781 |
| CRRT/HD | 2.86 | (1.19–6.88) | 0.019 |
| Low-dose steroids | 3.35 | (1.42–7.91) | 0.006 |
| Sedation | 0.99 | (0.88–1.10) | 0.825 |
| Parenteral nutrition | 0.93 | (0.82–1.05) | 0.241 |
| Enteral nutrition | 0.37 | (0.16–0.85) | 0.019 |
| Platelet transfusion | 1.46 | (1.10–1.92) | 0.008 |
| Low-molecular-weight heparin | 0.90 | (0.80–1.01) | 0.067 |
| Surgical procedures | 0.51 | (0.22–1.19) | 0.119 |
| Adjusted odds ratio (95% CI) | |||
| Multivariate logistic regression analysis | OR | 95% CI |
|
| Medical admission type | 3.92 | (1.18–12.99) | 0.025 |
| Chronic corticosteroid treatment | 14.21 | (1.90–106.44) | 0.010 |
| SOFA_0 | 1.25 | (1.10–1.43) | 0.001 |
aFactors with significant interaction with gender; see under Results and Figure 2 for further information.
Unadjusted OR = univariate analysis with hospital death as dependent variable; adjusted OR = multivariate stepwise backward logistic regression analysis, adjusted for age and gender, hospital death as dependent variable.